Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. Ardeshna KM, et al. Among authors: ferhanoglu b. Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4. Lancet Oncol. 2014. PMID: 24602760 Clinical Trial.
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience.
Özbalak M, Güzel Mastanzade M, Özlük Ö, Tiryaki TO, Erdem S, Özbalak EP, Elverdi T, Yönal Hindilerden İ, Altay AY, Yeğen G, Eşkazan AE, Ar MC, Yenerel MN, Soysal T, Nalçacı M, Ferhanoğlu B, Kalayoğlu Beşışık S. Özbalak M, et al. Among authors: ferhanoglu b. Turk J Haematol. 2022 Dec 1;39(4):254-261. doi: 10.4274/tjh.galenos.2022.2022.0142. Epub 2022 Jun 3. Turk J Haematol. 2022. PMID: 35657203 Free PMC article.
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.
Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Goker H, Baslar Z, Ferhanoglu B. Salihoglu A, et al. Among authors: ferhanoglu b. Ann Hematol. 2015 Mar;94(3):415-20. doi: 10.1007/s00277-014-2215-9. Epub 2014 Sep 18. Ann Hematol. 2015. PMID: 25231929 Free PMC article.
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, van de Velde H, Enny C, Rizo A, Ferhanoglu B. Offner F, et al. Among authors: ferhanoglu b. Blood. 2015 Oct 15;126(16):1893-901. doi: 10.1182/blood-2015-03-632430. Epub 2015 Jul 31. Blood. 2015. PMID: 26232170 Free PMC article. Clinical Trial.
Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
Öztürk E, Özbalak M, Berk S, Erdoğan I, Avşar E, Dolgun A, Çetiner M, Mandel NM, Yalnız FF, Elverdi T, Salihoğlu A, Eşkazan AE, Ar MC, Öngören Ş, Başlar Z, Aydın Y, Soysal T, Ferhanoğlu B. Öztürk E, et al. Among authors: ferhanoglu b. Leuk Lymphoma. 2016 May;57(5):1211-4. doi: 10.3109/10428194.2015.1079319. Epub 2015 Oct 12. Leuk Lymphoma. 2016. PMID: 26294270 No abstract available.
Rituximab desensitization in three patients with severe rituximab allergy.
Öztürk E, Özyiğit LP, Öztürk AB, Akay MO, Çetiner M, Ferhanoğlu B. Öztürk E, et al. Among authors: ferhanoglu b. Curr Probl Cancer. 2017 Sep-Oct;41(5):349-354. doi: 10.1016/j.currproblcancer.2017.07.003. Epub 2017 Jul 27. Curr Probl Cancer. 2017. PMID: 28860080
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
Beköz H, Karadurmuş N, Paydaş S, Türker A, Toptaş T, Fıratlı Tuğlular T, Sönmez M, Gülbaş Z, Tekgündüz E, Kaya AH, Özbalak M, Taştemir N, Kaynar L, Yıldırım R, Karadoğan I, Arat M, Pepedil Tanrıkulu F, Özkocaman V, Abalı H, Turgut M, Kurt Yüksel M, Özcan M, Doğu MH, Kabukçu Hacıoğlu S, Barışta I, Demirkaya M, Köseoğlu FD, Toprak SK, Yılmaz M, Demirkürek HC, Demirkol O, Ferhanoğlu B. Beköz H, et al. Among authors: ferhanoglu b. Ann Oncol. 2017 Oct 1;28(10):2496-2502. doi: 10.1093/annonc/mdx341. Ann Oncol. 2017. PMID: 28961828 Free article.
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W. Younes A, et al. Among authors: ferhanoglu b. Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11. Lancet Haematol. 2019. PMID: 30642819 Clinical Trial.
95 results